An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
Conditions
- Metastatic Colorectal Cancer
Interventions
- DRUG: Regorafenib (Stivarga, BAY73-4506)
Sponsor
Bayer